NL300270I1 - Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes. - Google Patents

Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.

Info

Publication number
NL300270I1
NL300270I1 NL300270C NL300270C NL300270I1 NL 300270 I1 NL300270 I1 NL 300270I1 NL 300270 C NL300270 C NL 300270C NL 300270 C NL300270 C NL 300270C NL 300270 I1 NL300270 I1 NL 300270I1
Authority
NL
Netherlands
Prior art keywords
disintegrated
particles
preparation
human papillomavirus
papillomavirus vaccine
Prior art date
Application number
NL300270C
Other languages
English (en)
Dutch (nl)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300270(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NL300270I1 publication Critical patent/NL300270I1/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NL300270C 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes. NL300270I1 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles
PCT/US2000/007595 WO2000057906A1 (en) 1999-03-26 2000-03-22 Human papillomavirus vaccine with disassembled and reassembled virus-like particles

Publications (1)

Publication Number Publication Date
NL300270I1 true NL300270I1 (nl) 2007-05-01

Family

ID=26824774

Family Applications (3)

Application Number Title Priority Date Filing Date
NL300270C NL300270I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.
NL300269C NL300269I2 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin
NL300268C NL300268I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NL300269C NL300269I2 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin
NL300268C NL300268I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.

Country Status (19)

Country Link
US (2) US6245568B1 (enExample)
EP (1) EP1165126B1 (enExample)
JP (1) JP4594534B2 (enExample)
KR (1) KR20020013516A (enExample)
AR (1) AR023166A1 (enExample)
AT (1) ATE339222T1 (enExample)
AU (1) AU778937B2 (enExample)
CA (1) CA2368391C (enExample)
CY (4) CY1105779T1 (enExample)
DE (4) DE122007000034I1 (enExample)
DK (1) DK1165126T3 (enExample)
ES (1) ES2270822T3 (enExample)
FR (1) FR07C0026I2 (enExample)
LT (1) LTC1165126I2 (enExample)
LU (3) LU91328I2 (enExample)
NL (3) NL300270I1 (enExample)
PT (1) PT1165126E (enExample)
SI (1) SI1165126T1 (enExample)
WO (1) WO2000057906A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
EP1250593B1 (en) * 1999-12-09 2009-03-25 Medimmune, Inc. IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003068804A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CA2503871C (en) 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. An immunogenic composition for generating an immune response against polio virus
PT1572233E (pt) 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20080131928A1 (en) * 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
EP1841474A2 (en) * 2005-01-25 2007-10-10 Wyeth Research Ireland Limited Method for diafiltration
JP2009501520A (ja) * 2005-07-14 2009-01-22 メイヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パラミクソウイルス科ウイルス調製物
WO2007020871A1 (ja) * 2005-08-12 2007-02-22 Astellas Pharma Inc. デプシペプチド含有注射液
WO2007027076A1 (es) * 2005-09-01 2007-03-08 Nuno Ayala Jose Luis Formula estabilizadora de vacunas con antígenos vivos para su uso en sistemas de vacunación masiva
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8962262B2 (en) * 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
ES2660762T3 (es) * 2009-09-03 2018-03-26 Becton, Dickinson And Company Métodos y composiciones para lisis química directa
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US20200010850A1 (en) 2017-02-17 2020-01-09 The USA, as represeented by the Secretary, Dept. of Health and Human Services Efficient cell free production of papillomavirus gene transfer vectors
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法
TW202334423A (zh) * 2021-12-15 2023-09-01 美商旗艦先鋒創新公司 表面經修飾之病毒顆粒及模組化之病毒顆粒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515056A (ja) * 1997-02-06 2002-05-21 メルク エンド カンパニー インコーポレーテッド ワクチン用チメロサールフリー保存剤
WO1998044944A2 (en) 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
AU755679B2 (en) 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
NL300268I1 (nl) 2007-05-01
LU91328I2 (fr) 2007-05-14
SI1165126T1 (sl) 2006-12-31
WO2000057906A1 (en) 2000-10-05
CY2007009I2 (el) 2010-07-28
EP1165126A1 (en) 2002-01-02
FR07C0026I2 (fr) 2012-08-03
CY2007010I1 (el) 2009-11-04
CY1105779T1 (el) 2010-07-28
LTC1165126I2 (lt) 2020-04-27
CY2007009I1 (el) 2010-07-28
DE60030698D1 (de) 2006-10-26
NL300269I2 (nl) 2008-07-01
FR07C0026I1 (enExample) 2007-04-27
NL300269I1 (nl) 2007-05-01
LU91326I2 (fr) 2007-05-14
CY2007008I1 (el) 2009-11-04
CA2368391A1 (en) 2000-10-05
LTPA2007002I1 (lt) 2020-03-25
EP1165126B1 (en) 2006-09-13
LU91328I9 (enExample) 2019-03-01
US6245568B1 (en) 2001-06-12
US20010021385A1 (en) 2001-09-13
AU3909300A (en) 2000-10-16
DE122007000032I1 (de) 2007-08-09
LU91327I2 (fr) 2007-05-14
JP2002540167A (ja) 2002-11-26
ES2270822T3 (es) 2007-04-16
ATE339222T1 (de) 2006-10-15
LU91326I9 (enExample) 2018-12-31
DE60030698T2 (de) 2007-07-19
DE122007000034I1 (de) 2007-08-09
CY2007010I2 (el) 2009-11-04
AU778937B2 (en) 2004-12-23
AR023166A1 (es) 2002-09-04
CA2368391C (en) 2011-06-07
LU91327I9 (enExample) 2019-03-01
DK1165126T3 (da) 2007-01-08
DE122007000033I1 (de) 2007-08-09
PT1165126E (pt) 2006-12-29
KR20020013516A (ko) 2002-02-20
JP4594534B2 (ja) 2010-12-08
CY2007008I2 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
NL300268I1 (nl) Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.
EE200200151A (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
AU2003235707A8 (en) Immunogenic preparations and vaccines on the basis of mrna
AU2003227533A8 (en) Virus like particle from papillomavirus and their use in vaccine
AU2002241534A1 (en) Disposable aerosol generator system and methods for administering the aerosol
AP2004003136A0 (en) Virus-like particles of human papillomavirus
EP1465693A4 (en) DISPOSABLE AEROSOL GENERATION SYSTEM AND METHOD FOR ADMINISTERING THE AEROSOL
IL143634A0 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
AU2002220151A1 (en) Method and system for the detection of heart disease
EP1322326A4 (en) VACCINES DIRECTED TO THE INNE IMMUNE SYSTEM
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
AU2001266392A1 (en) The controlled release preparation of insulin and its method
EP1543841A4 (en) SOLID PHARMACEUTICAL NANO FORMULATION AND MANUFACTURING METHOD THEREFOR
NL1016891A1 (nl) Caloriearme notenboters en werkwijzen voor het bereiden daarvan.
AU2001269640A1 (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU2000279747A1 (en) Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
AU6964001A (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
AU2003278175A1 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
ZA200107602B (en) Tuberculosis antigens and methods of use therefor.
AU2001248839A1 (en) Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same
EP1567188A4 (en) MODIFIED VIRUS PARTICLES WITH IMMUNOGENIC PROPERTIES AND REDUCED LIPID CONTENT FOR THE TREATMENT AND PREVENTION OF INFECTION DISEASES
AU2273301A (en) Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer
WO2005123086A3 (en) Ziprasidone dosage form
EP1632225A4 (en) DRUG NANOPARTICLE, PROCESS AND APPARATUS FOR PREPARING PHARMACEUTICAL PREPARATION THEREFROM